Presència del CRAI a les xarxes socials

Podeu consultar la Jornada completa al camp recurs relaciona

Experiencia en gestión de redes sociales en el CRAI de la UB

El CRAI de la Universidad de Barcelona (CRAI UB) empezó a investigar y a utilizar las redes sociales entre finales del 2006 y principios del 2007. En aquellos momentos los blogs fueron las primeras redes que en las que participamos. El hecho de permitir comunicarnos con los usuarios a través de noticias de interés y de recibir sus comentarios hizo que los blogs fueran un medio dinámico en contraste con las tradicionales páginas web estáticas. El primer blog que elaboramos fue el del CRAI Biblioteca de Letras. Lentamente y en función de su viabilidad se impulsó, desde la unidad transversal de Proyectos del CRAI UB, la presencia del resto de CRAI Bibliotecas en las redes sociales. Con la aparición de Facebook se abrió una nueva posibilidad de comunicación e interactividad con los usuarios potenciales del CRAI UB, que se vio favorecida también con la irrupción de Twitter. En un principio, se empezaron a crear cuentas con perfiles personales y, cuando fue posible, pasaron a ser cuentas institucionales. Si hablamos de un público universitario como el nuestro, es Facebook la que arrastra mayor audiencia y, por consiguiente, la que permite llegar a un mayor número de usuarios. Esta posibilidad de compartir información de forma inmediata y sin demasiado esfuerzo añadido fue el impulso definitivo a la generalización de las redes sociales en la mayoría de los CRAI Bibliotecas

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

HIV; Integrase strand transfer inhibitorsVIH; Inhibidores de transferencia de cadena de integrasaVIH; Inhibidors de transferència de cadena de la integrasaIntroduction: Second-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients. Methods: Real-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naïve patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) ≥200 copies/mL at 24 weeks or as a single determination of VL ≥1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated. Results: Virological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naïve patients with CD4+ nadir <100 cells/μL were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles. Discussion: Whereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available.This study received funding from ViiV Healthcare and Fight Infections Foundation. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication

Synthesis of steroid-oligonucleotide conjugates for a DNA site-encoded SPR immunosensor

The excellent self-assembling properties of DNA and the excellent specificity of the antibodies to detect analytes of small molecular weight under competitive conditions have been combined in this study. Three oligonucleotide sequences (N1up, N2up, and N3up) have been covalently attached to three steroidal haptens (8, hG, and 13) of three anabolic-androgenic steroids (AAS), stanozolol (ST), tetrahydrogestrinone (THG), and boldenone (B), respectively. The synthesis of steroid-oligonucleotide conjugates has been performed by the reaction of oligonucleotides carrying amino groups with carboxyl acid derivatives of steroidal haptens. Due to the chemical nature of the steroid derivatives, two methods for coupling the haptens and the ssDNA have been studied: a solid-phase coupling strategy and a solution-phase coupling strategy. Specific antibodies against ST, THG, and B have been used in this study to asses the possibility of using the self-assembling properties of the DNA to prepare biofunctional SPR gold chips based on the immobilization of haptens, by hybridization with the complementary oligonucleotide strands possessing SH groups previously immobilized. The capture of the steroid-oligonucleotide conjugates and subsequent binding of the specific antibodies can be monitored on the sensogram due to variations produced on the refractive index on top of the gold chip. The resulting steroid-oligonucleotide conjugates retain the hybridization and specific binding properties of oligonucleotides and haptens as demonstrated by thermal denaturation experiments and surface plasmon resonance (SPR).This work was supported by grants from the Ministry of Science and Innovation, MICINN (MAT2011-29335-C03-01 and CTQ2010-20541-C03-01), CCEE (FUNMOL, FP7-NMP-213382-2), Generalitat de Catalunya (2009/SGR/1343, 2009/SGR/208), and CIBER-BBN. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. Núria Tort has a FI_B fellowship from the AGAUR (Agència de Gestió d’Ajuts Universitaris i de Recerca) of the (Generalitat de Catalunya) Government of Catalonia.Peer reviewe

BCN Rocks: aprendiendo geología urbana a través de una aplicación App interactiva

BCN Rocks is an application (App) for personal mobile devices (Android and iOS versions) suitable for secondary and high school students as well as people without background in Earth Sciences. The main objective of this App is to learn geology using the city facades and pavements of two emblematic spaces of the city of Barcelona, the Passeig de Gràcia and the Barri Gòtic. The application has three main sections (ELEMENTS, EXPLORE, and LABORATORY) that are intended to satisfy the different needs of users. In the first section, Elements, the user will find all the information about rocks forming the selected buildings as well as a brief explanation about the history and architecture of each edifice. The second section, Explore, aims to arise the curiosity of users. In this sense, several routes are proposed according to different criteria including geographic position and age of the edifices. Finally, the third section, Laboratory, allows all users to investigate several geological aspects by means of interactive experiments.Este trabajo se enmarca en un proyecto financiado por la Fundación Española para la Ciencia y la Tecnología, FECYT (ref. 8524) en el que ha participado la Universitat de Barcelona, el Instituto de Ciencias de la Tierra Jaume Almera del Consejo Superior de Investigaciones Científicas (ICTJA-CSIC) y la empresa FUSTA. AG agradece su contrato Ramón y Cajal (RYC-2012-11024).Peer Reviewe

Barcelona Rocks, A mobile App to learn Geology in your city.

Barcelona Rocks is an application for personal mobile devices suitable for secondary and high school students as well as the general public without a solid background in Earth Sciences

Probiotic effects on immunity and microbiome in HIV-1 discordant patients

Some HIV-1 infected patients are unable to completely recover normal CD4+ T-cell (CD4+) counts after achieving HIV-1 suppression with combined Antiretroviral Therapy (cART), hence being classified as immuno-discordant. The human microbiome plays a crucial role in maintaining immune homeostasis and is a potential target towards immune reconstitution. RECOVER (NCT03542786) was a double-blind placebo-controlled clinical trial designed to evaluate if the novel probiotic i3.1 (AB-Biotics, Sant Cugat del Vallès, Spain) was able to improve immune reconstitution in HIV-1 infected immuno-discordant patients with stable cART and CD4+ counts <500 cells/mm3. The mixture consisted of two strains of L. plantarum and one of P. acidilactici, given with or without a fiber-based prebiotic. 71 patients were randomized 1:2:2 to Placebo, Probiotic or probiotic + prebiotic (Synbiotic), and were followed over 6 months + 3-month washout period, in which changes on systemic immune status and gut microbiome were evaluated. Primary endpoints were safety and tolerability of the investigational product. Secondary endpoints were changes on CD4+ and CD8+ T-cell (CD8+) counts, inflammation markers and faecal microbiome structure, defined by alpha diversity (Gene Richness), beta diversity (Bray-Curtis) and functional profile. Comparisons across/within groups were performed using standard/paired Wilcoxon test, respectively. Adverse event (AE) incidence was similar among groups (53%, 33%, and 55% in the Placebo, Probiotic and Synbiotic groups, respectively, the most common being grade 1 digestive AEs: flatulence, bloating and diarrhoea. Two grade 3 AEs were reported, all in the Synbiotic group: abdominal distension (possibly related) and malignant lung neoplasm (unrelated), and 1 grade 4 AE in the Placebo: hepatocarcinoma (unrelated). Synbiotic exposure was associated with a higher increase in CD4+/CD8+ T-cell (CD4/CD8) ratio at 6 months vs baseline (median=0.76(IQR=0.51) vs 0.72(0. 45), median change= 0.04(IQR=0.19), p = 0.03). At month 9, the Synbiotic group had a significant increase in CD4/CD8 ratio (0.827(0.55) vs 0.825(0.53), median change = 0.04(IQR=0.15), p= 0.02) relative to baseline, and higher CD4+ counts (447 (157) vs. 342(73) counts/ml, p = 0.03), and lower sCD14 values (2.16(0.67) vs 3.18(0.8), p = 0.008) than Placebo. No effect in immune parameters was observed in the Probiotic arm. None of the two interventions modified microbial gene richness (alpha diversity). However, intervention as categorical variable was associated with slight but significant effect on Bray-Curtis distance variance (Adonis R2 = 0.02, p = 0.005). Additionally, at month 6, Synbiotic intervention was associated with lower pathway abundances vs Placebo of Assimilatory Sulphate Reduction (8.79·10 -6 (1.25·10 -5) vs. 1.61·10 -5 (2.77·10 -5), p = 0.03) and biosynthesis of methionine (2.3·10 -5 (3.17·10 -5) vs. 4·10 -5 (5.66·10 -5), p = 0.03) and cysteine (1.83·10 -5 (2.56·10 -5) vs. 3.3·10 -5 (4.62·10 -5), p = 0.03). At month 6, probiotic detection in faeces was associated with significant decreases in C Reactive Protein (CRP) vs baseline (11.1(22) vs. 19.2(66), median change= -2.7 (13.2) ug/ml, p = 0.04) and lower IL-6 values (0.58(1.13) vs. 1.17(1.59) ug/ml, p = 0.02) when compared with samples with no detectable probiotic. No detection of the probiotic was associated with higher CD4/CD8 ratio at month 6 vs baseline (0.718(0.57) vs. 0.58(0.4), median change = 0.4(0.2), p = 0.02). After washout, probiotic non-detection was also associated with a significant increase in CD4+ counts (457(153) vs. 416(142), median change = 45(75), counts/ml, p = 0.005) and CD4/CD8 ratio (0.67(0.5) vs 0.59(0.49), median change = 0.04 (0.18), p = 0.02). A synbiotic intervention with L. plantarum and P. acidilactici was safe and led to small increases in CD4/CD8 ratio and minor reductions in sCD14 of uncertain clinical significance. A probiotic with the same composition was also safe but did not achieve any impact on immune parameters or faecal microbiome composition

Barcelona Rocks, a mobile app to learn geology in your city

Barcelona Rocks is an application for personal mobile devices suitable for secondary and high school students as well as the general public without a solid background in Earth Sciences. The main objective of this app is to teach Geology using as learning resource our city façades and pavements. Additionally, Barcelona Rocks provides a short explanation about the significance of the appearance of the different rock types at the different historical periods of the city. Although it has been designed as a playful learning resource for secondary school students, the level of knowledge also allows bringing some basic concepts and principles of Earth Sciences to the general public, irrespective of age.Peer Reviewe

BCN Rocks: aprendiendo geología urbana a través de una aplicación App interactiva.

Barcelona Rocks (BCN Rocks) es una aplicación (App) para dispositivos móviles personales (con versiones para Android y iOS) apta para ser utilizada por estudiantes de Enseñanza Secundaria Obligatoria (ESO) y Bachillerato, y para el público en general, con el objetivo de aprender geología a partir de recursos didácticos proporcionados por las rocas de las fachadas y pavimentos de dos zonas emblemáticas y céntricas de la ciudad de Barcelona como son el Passeig de Gràcia y el Barri Gòtic. La aplicación presenta tres grandes apartados "ELEMENTOS", "EXPLORA" y "LABORATORIO" que pretenden satisfacer diversas facetas del usuario. En el apartado Elementos, el usuario encontrará el conjunto de edificios que contiene la aplicación, toda la información sobre las rocas que los forman, así como una breve explicación sobre la historia y arquitectura de cada uno de ellos. Con el apartado Explora, se pretende despertar la curiosidad o la parte más expedicionaria del usuario. Para ello se proponen una serie de rutas que pueden realizarse siguiendo, bien el criterio de posición geográfica de los edificios incluidos en la App, bien teniendo en cuenta la antigüedad de las construcciones (desde la Barcino romana hasta la Barcelona actual). Finalmente, el partado Laboratorio, permite al usuario investigar distintos aspectos geológicos mediante experimentos interactivos

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients. MethodsReal-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naive patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) & GE;200 copies/mL at 24 weeks or as a single determination of VL & GE;1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated. ResultsVirological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naive patients with CD4+ nadir <100 cells/& mu;L were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles. DiscussionWhereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available